Adverse events · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…
1 finding from 1 review
no estimate extracted
10 participants
Very low
Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Health‐related quality of life Assessed by: SeiQoL‐DW (higher scores mean better quality of life) · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Adverse effects · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
Botulinum toxin injection may leads to lower adverse effects compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
no estimate extracted
1 participants
Moderate
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus may leads to higher clinical remission compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus may leads to higher clinical improvement compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Live birth rate per couple · patients with male subfertility
It is very uncertain whether antioxidants changes live birth rate per couple randomised compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Clinical pregnancy rate · patients with male subfertility
Antioxidants may leads to higher clinical pregnancy rate per couple randomised compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse events ‐ Miscarriage · patients with male subfertility
It is very uncertain whether antioxidants changes adverse events ‐ Miscarriage compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · patients with male subfertility
Antioxidants may leads to higher adverse events ‐ Gastrointestinal compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · newly‐diagnosed EOC
It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy changes any severe adverse event (grade 3 or higher) (G3+ SevAE ) compared with placebo (maintenance therapy) (very low certainty).
1 finding from 1 review
Outcomes · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · platinum‐sensitive recurrent EOC
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with placebo after chemotherapy (maintenance therapy) (moderate certainty).
1 finding from 1 review
Progression‐free survival · platinum‐sensitive recurrent EOC
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… leads to lower progression‐free survival (PFS) compared with placebo after chemotherapy (maintenance therapy) (high certainty).
1 finding from 1 review
QoL · platinum‐sensitive recurrent EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… may leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with placebo after chemotherapy (maintenance therapy) (low certainty).
1 finding from 1 review
Outcomes · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found